Search Legislation

The Human Medicines Regulations 2012

 Help about what version

What Version

  • Latest available (Revised)
  • Original (As made)
 Help about advanced features

Advanced Features

Changes over time for: SCHEDULE 7A

 Help about opening options

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines Regulations 2012, SCHEDULE 7A. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Regulation 45N(5)(b)

[F1SCHEDULE 7AU.K.Information to be provided for registration as an importer, manufacturer or distributor of active substances

This schedule has no associated Explanatory Memorandum

Textual Amendments

1.  The name and address of the applicant.U.K.

2.  The name and address of the person (if any) making the application on the applicant’s behalf.U.K.

3.  The address of each of the premises where any operations to which the registration relates are to be carried out.U.K.

4.  The address of any premises not mentioned by virtue of the above requirement, where—U.K.

(a)the applicant proposes to keep any living animals, from which substance(s) used in the production of the active substance(s) to which the application relates are to be derived;

(b)materials of animal origin from which an active substance is to be derived, as mentioned in the above sub-paragraph, are to be kept.

5.  The address of each of the premises where active substances are to be stored, or from which active substances are to be distributed.U.K.

6.  The address of each of the premises where any testing associated with the manufacture or assembly of active substances to which the registration relates.U.K.

7.  The name, address, qualifications and experience of the person whose duty it will be to supervise any manufacturing operations, and the name and job title of the person to whom they report.U.K.

8.  The name, address, qualifications and experience of the person who will have responsibility for the quality control of active substances, and the name and job title of the person to whom they report.U.K.

9.  The name, address, qualifications and experience of the person whose duty it will be to supervise any importation, storage or distribution operations, and the name and job title of the person to whom they report.U.K.

10.  The name, address and qualifications of the person to be responsible for any animals kept as mentioned in paragraph 4(a).U.K.

11.  The name, address and qualifications of the person to be responsible for the culture of any living tissue for use in the manufacture of an active substance.U.K.

12.  For each active substance to be manufactured, imported, or distributed—U.K.

(a)the CAS registration number assigned to that active substance by the Chemical Abstracts Service, a division of the American Chemical Society;

(b)where applicable, the Anatomical Therapeutic Category code assigned to that active substance under the Anatomical Therapeutic Chemical Classification System used for the classification of drugs by the World Health Organisation’s Collaborating Centre for Drug Statistics Methodology;

(c)either—

(i)the International Union of Pure and Applied Chemistry nomenclature, or

(ii)the common name; and

(d)the intended quantities of each active substance to be manufactured, imported or distributed.

13.  Details of the operations to which the registration relates, including a statement of whether they include—U.K.

(a)the manufacture of active substances;

(b)the importation of active substances F2...;

(c)the storage of active substances; or

(d)the distribution of active substances.

14.  A statement of the facilities and equipment available at each of the premises where active substances are to be manufactured, stored or distributed.U.K.

15.  A statement as to whether the particular active substances are intended for—U.K.

(a)use in a medicinal product with an EU marketing authorisation;

(b)use in a special medicinal product; or

(c)export F3....

16.  A separate statement in respect of each of the premises mentioned in the application of—U.K.

(a)the manufacturing, storage or distribution operations carried out at those sites, and the specific active substances to which those activities relate; and

(b)the equipment available at those premises for carrying out those activities.

17.  A statement of the authority conferred on the person responsible for quality control to reject unsatisfactory active substances.U.K.

18.  A description of the arrangements for the identification and storage of materials before and during the manufacture of active substances.U.K.

19.  A description of the arrangements for the identification and storage of active substances.U.K.

20.  A description of the arrangements at each of the premises where the applicant proposes to store active substances for ensuring, as far as practicable, the turn-over of stocks of active substances.U.K.

21.  A description of the arrangements for maintaining—U.K.

(a)production records, including records of manufacture and assembly;

(b)records of analytical and other tests used in the course of manufacture or assembly for ensuring compliance of materials use in manufacture, or of active substances, with the specification for such materials or active substances;

(c)records of importation;

(d)records of storage and distribution.

22.  A description of the arrangements for keeping reference samples of—U.K.

(a)materials used in the manufacture of active substances; and

(b)active substances.

23.  Where the application relates to active substances intended for use in an advanced therapy medicinal product, an outline of the arrangements for maintaining records to allow traceability containing sufficient detail to enable the linking of an active substance to the advanced therapy medicinal product it was used in the manufacture of and vice versa.U.K.

24.  Details of—U.K.

(a)any manufacturing, importation, storage or distribution operations, other than those to which the application for registration relates, carried on by the applicant on or near each of the premises, and

(b)the substances or articles to which those operations relate.]

Back to top

Options/Help

Print Options

You have chosen to open The Whole Instrument

The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

You have chosen to open The Whole Instrument as a PDF

The Whole Instrument you have selected contains over 200 provisions and might take some time to download.

Would you like to continue?

You have chosen to open the Whole Instrument

The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

You have chosen to open the Whole Instrument without Schedules

The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

You have chosen to open Schedules only

The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

Explanatory Memorandum

Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Impact Assessments

Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:

  • Why the government is proposing to intervene;
  • The main options the government is considering, and which one is preferred;
  • How and to what extent new policies may impact on them; and,
  • The estimated costs and benefits of proposed measures.
Close

Timeline of Changes

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources